Olema Oncology, Inc.
corporate_fare Company Profile
Olema Oncology, Inc. (NASDAQ:OLMA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for OLMA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for OLMA spans 8-K, 10-Q, 144, 10-K.
Recent high-impact activity:
- Olema Q3 Loss Widens to $73.6M; Cash Falls to $413.8M Ahead of Q1 2027 OPERA-01 Data
- Olema Q2 2026: Cash Runway Extended to Mid-2028, OPERA-01 Top-Line Data Expected Q1 2027
- Olema Partners with Bayer to Advance Prostate Cancer Drug OP-3136
- Olema Pharmaceuticals Partners with Bayer for Prostate Cancer Clinical Trial
- Olema's OP-3136 Phase 1 Data 'Encouraging' with Tumor Shrinkage, Partial Responses
Financial Snapshot
Short Interest & Short Volume
11.86 days to coverFINRA reported short interest of 17,124,622 shares in OLMA as of the October 30, 2026 settlement, a 9.2% increase from the prior period — about 11.9 days to cover at its recent average daily volume. On November 20, 2026, 67.0% of OLMA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.